Nrf2 expression in endometrial serous carcinomas and its precancers

Ning Chen, Xiaofang Yi, Nisreen Abushahin, Shujie Pang, Donna Zhang, Beihua Kong, Wenxin Zheng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Endometrial serous carcinoma (ESC) is the most aggressive subtype of endometrial cancer. Its aggressive behavior and poor clinical outcome may be partially attributed to lack of early diagnostic markers and unclear pathogenesis. The transcription factor Erythroid-E2-related factor 2 (Nrf2) is a recently identified protein marker, which plays a role in carcinogenesis as well as responsible for poor prognosis of many human cancers. The aim of this study is to determine the Nrf2 expression in benign endometrium (n=28), endometrial cancers (n=122) as well as their precursor lesions (n=81) trying to see whether Nrf2 has any diagnostic usage and is potentially involved in endometrial carcinogenesis. The level of Nrf2 was evaluated by immunohistochemical (IHC) and verified by using Western blots. Among the malignant cases, Nrf2 was positive in 28 (68%) of 50 ESCs, which was significantly more than in 3 (6%) of 50 endometrioid carcinomas (p < 0.001) and 2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers. Among endometrial precursor lesions, both serous endometrial glandular dysplasia (EmGD, 40%) and serous endometrial intraepithelial carcinoma (EIC, 44%) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0%), clear cell EmGD (10%), and clear cell EIC (25%), respectively. We conclude that Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation. Alteration of Nrf2 expression may represent one of the early molecular events in ESC carcinogenesis and overexpression of Nrf2 may used as a diagnostic marker in surgical pathology.

Original languageEnglish (US)
Pages (from-to)85-96
Number of pages12
JournalInternational Journal of Clinical and Experimental Pathology
Volume4
Issue number1
StatePublished - Nov 2 2011

Fingerprint

Endometrial Neoplasms
Carcinogenesis
Endometrioid Carcinoma
Endometrial Hyperplasia
Surgical Pathology
Carcinoma in Situ
Endometrium
Neoplasms
Transcription Factors
Western Blotting
Carcinoma
Proteins

Keywords

  • Endometrial cancer
  • Endometrial glandular dysplasia
  • Endometrial serous carcinoma
  • Nrf2
  • Precancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Nrf2 expression in endometrial serous carcinomas and its precancers. / Chen, Ning; Yi, Xiaofang; Abushahin, Nisreen; Pang, Shujie; Zhang, Donna; Kong, Beihua; Zheng, Wenxin.

In: International Journal of Clinical and Experimental Pathology, Vol. 4, No. 1, 02.11.2011, p. 85-96.

Research output: Contribution to journalArticle

Chen, N, Yi, X, Abushahin, N, Pang, S, Zhang, D, Kong, B & Zheng, W 2011, 'Nrf2 expression in endometrial serous carcinomas and its precancers', International Journal of Clinical and Experimental Pathology, vol. 4, no. 1, pp. 85-96.
Chen, Ning ; Yi, Xiaofang ; Abushahin, Nisreen ; Pang, Shujie ; Zhang, Donna ; Kong, Beihua ; Zheng, Wenxin. / Nrf2 expression in endometrial serous carcinomas and its precancers. In: International Journal of Clinical and Experimental Pathology. 2011 ; Vol. 4, No. 1. pp. 85-96.
@article{3e68567a04e74031b39a2fd622760eb9,
title = "Nrf2 expression in endometrial serous carcinomas and its precancers",
abstract = "Endometrial serous carcinoma (ESC) is the most aggressive subtype of endometrial cancer. Its aggressive behavior and poor clinical outcome may be partially attributed to lack of early diagnostic markers and unclear pathogenesis. The transcription factor Erythroid-E2-related factor 2 (Nrf2) is a recently identified protein marker, which plays a role in carcinogenesis as well as responsible for poor prognosis of many human cancers. The aim of this study is to determine the Nrf2 expression in benign endometrium (n=28), endometrial cancers (n=122) as well as their precursor lesions (n=81) trying to see whether Nrf2 has any diagnostic usage and is potentially involved in endometrial carcinogenesis. The level of Nrf2 was evaluated by immunohistochemical (IHC) and verified by using Western blots. Among the malignant cases, Nrf2 was positive in 28 (68{\%}) of 50 ESCs, which was significantly more than in 3 (6{\%}) of 50 endometrioid carcinomas (p < 0.001) and 2 (13{\%}) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers. Among endometrial precursor lesions, both serous endometrial glandular dysplasia (EmGD, 40{\%}) and serous endometrial intraepithelial carcinoma (EIC, 44{\%}) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0{\%}), clear cell EmGD (10{\%}), and clear cell EIC (25{\%}), respectively. We conclude that Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation. Alteration of Nrf2 expression may represent one of the early molecular events in ESC carcinogenesis and overexpression of Nrf2 may used as a diagnostic marker in surgical pathology.",
keywords = "Endometrial cancer, Endometrial glandular dysplasia, Endometrial serous carcinoma, Nrf2, Precancer",
author = "Ning Chen and Xiaofang Yi and Nisreen Abushahin and Shujie Pang and Donna Zhang and Beihua Kong and Wenxin Zheng",
year = "2011",
month = "11",
day = "2",
language = "English (US)",
volume = "4",
pages = "85--96",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Nrf2 expression in endometrial serous carcinomas and its precancers

AU - Chen, Ning

AU - Yi, Xiaofang

AU - Abushahin, Nisreen

AU - Pang, Shujie

AU - Zhang, Donna

AU - Kong, Beihua

AU - Zheng, Wenxin

PY - 2011/11/2

Y1 - 2011/11/2

N2 - Endometrial serous carcinoma (ESC) is the most aggressive subtype of endometrial cancer. Its aggressive behavior and poor clinical outcome may be partially attributed to lack of early diagnostic markers and unclear pathogenesis. The transcription factor Erythroid-E2-related factor 2 (Nrf2) is a recently identified protein marker, which plays a role in carcinogenesis as well as responsible for poor prognosis of many human cancers. The aim of this study is to determine the Nrf2 expression in benign endometrium (n=28), endometrial cancers (n=122) as well as their precursor lesions (n=81) trying to see whether Nrf2 has any diagnostic usage and is potentially involved in endometrial carcinogenesis. The level of Nrf2 was evaluated by immunohistochemical (IHC) and verified by using Western blots. Among the malignant cases, Nrf2 was positive in 28 (68%) of 50 ESCs, which was significantly more than in 3 (6%) of 50 endometrioid carcinomas (p < 0.001) and 2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers. Among endometrial precursor lesions, both serous endometrial glandular dysplasia (EmGD, 40%) and serous endometrial intraepithelial carcinoma (EIC, 44%) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0%), clear cell EmGD (10%), and clear cell EIC (25%), respectively. We conclude that Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation. Alteration of Nrf2 expression may represent one of the early molecular events in ESC carcinogenesis and overexpression of Nrf2 may used as a diagnostic marker in surgical pathology.

AB - Endometrial serous carcinoma (ESC) is the most aggressive subtype of endometrial cancer. Its aggressive behavior and poor clinical outcome may be partially attributed to lack of early diagnostic markers and unclear pathogenesis. The transcription factor Erythroid-E2-related factor 2 (Nrf2) is a recently identified protein marker, which plays a role in carcinogenesis as well as responsible for poor prognosis of many human cancers. The aim of this study is to determine the Nrf2 expression in benign endometrium (n=28), endometrial cancers (n=122) as well as their precursor lesions (n=81) trying to see whether Nrf2 has any diagnostic usage and is potentially involved in endometrial carcinogenesis. The level of Nrf2 was evaluated by immunohistochemical (IHC) and verified by using Western blots. Among the malignant cases, Nrf2 was positive in 28 (68%) of 50 ESCs, which was significantly more than in 3 (6%) of 50 endometrioid carcinomas (p < 0.001) and 2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers. Among endometrial precursor lesions, both serous endometrial glandular dysplasia (EmGD, 40%) and serous endometrial intraepithelial carcinoma (EIC, 44%) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0%), clear cell EmGD (10%), and clear cell EIC (25%), respectively. We conclude that Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation. Alteration of Nrf2 expression may represent one of the early molecular events in ESC carcinogenesis and overexpression of Nrf2 may used as a diagnostic marker in surgical pathology.

KW - Endometrial cancer

KW - Endometrial glandular dysplasia

KW - Endometrial serous carcinoma

KW - Nrf2

KW - Precancer

UR - http://www.scopus.com/inward/record.url?scp=79955109046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955109046&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 85

EP - 96

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 1

ER -